CoChat

Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors

Open access
Ho, Vincent Y., Yeh, Steven, Olsen, Timothy W., Bergstrom, Chris S., Yan, Jiong, Cribbs, Blaine E., Hubbard, G. Baker · 2013 · American Journal of Ophthalmology
Cited by 122

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Purpose To report results of aflibercept therapy in eyes with neovascular age-related macular degeneration previously treated with bevacizumab and/or ranibizumab. Design Retrospective, interventional, non-comparative, consecutive case series Methods Ninety-six eyes, 85 patients, with neovascular AMD that had previously received bevacizumab and/or ranibizumab were treated with aflibercept monthly for 3 months followed by a fourth injection within 2 months. Outcomes were determined 4 ± 1 months after the first aflibercept dose and included: proportion of patients gaining or losing ≥ 2 lines of best corrected visual acuity (BCVA), proportion remaining within ±1 line, mean change in logMAR VA, mean change in central foveal thickness, mean change in macular cube volume, and qualitative anatomic response as assessed by spectral-domain OCT. Results At baseline, 82 (85%) eyes had signs of active exudation despite a mean 17 previous anti-VEGF injections. At final visit, 82 (85%) remained stable within ±1 line, 7 (7%) gained and 7 (7%) lost ≥ 2 lines of BCVA. Mean logMAR VA showed minimal change 0.02 (range −0.46 to 0.70, P=0.14). Mean central foveal thickness decreased −18 microns (range −242 to 198, P=0.06). Mean macular volume decreased −0.27 mm3 (95% CI, −0.4 to −0.1, P = 0.004). On qualitative analysis, 4 (5%) eyes had complete resolution of exudative fluid, 40 (49%) partially resolved, 26 (32%) remained unchanged, and 12 (14%) worsened. Conclusion Aflibercept appears to be an effective alternative for neovascular AMD patients previously treated with bevacizumab and/or ranibizumab at 4 months follow-up. The majority of treated eyes demonstrated stable VA and anatomic improvements by SD-OCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2013.02.009

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 122

Metadata

Authors
Ho, V. Y., Yeh, S., Olsen, T. W., Bergstrom, C. S., Yan, J., Cribbs, B. E., & Hubbard, G. B.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2013-07
Volume
156
Issue
1
Pages
23-28.e2
ISSN
0002-9394 (ISSN-L)
OpenAlex
W2112069706
Cited by
122
References
8
FWCI
25.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors. https://app.cochat.ai/papers/10.1016/j.ajo.2013.02.009
The paper
Ho, V. Y., Yeh, S., Olsen, T. W., Bergstrom, C. S., Yan, J., Cribbs, B. E., & Hubbard, G. B. (2013). Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2013.02.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.